logo

Stock Screener

Forex Screener

Crypto Screener

ATNF

180 Life Sciences Corp. (ATNF)

$

7.04

-0.57 (-8.10%)


Key metrics

Financial statements

Free cash flow per share

Free cash flow per share

-0.5534

Market cap

Market cap

1.1 Billion

Price to sales ratio

Price to sales ratio

11.3 Thousand

Debt to equity

Debt to equity

0.2625

Current ratio

Current ratio

0.5797

Income quality

Income quality

0.3432

Average inventory

Average inventory

0

ROE

ROE

-1.4124



Technology

Technology

Technology – consumer electronics

Largecap

Largecap

With a market cap of 121,78 bil stock is ranked 1

Low risk

Low risk

ISS score of this stock is ranked 1


Company description

Profile

1180 Life Sciences Corp. is a clinical-stage biotechnology company focused on addressing unmet medical needs related to chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company has several product development platforms, including its fibrosis and anti-tumor necrosis factor (anti-TNF) platform, currently in Phase IIb clinical trials, targeting conditions related to fibrosis and Anti-TNF treatment. Additionally, the Synthetic Cannabidiol (CBD) Analogs platform is under preclinical trials, featuring synthetic derivatives of CBD, while the a7nAChR platform, designed for immune suppression, is also in preclinical trials, focusing on the alpha 7 nicotinic acetylcholine receptor. The company incurred an interest expense of $50,640.00 reflecting its debt servicing obligations. The operating income ratio is 0.00 indicating the company's operational profitability margin. The total costs and expenses for the company are $6,324,729.00 reflecting its overall spending. Moreover, the company reported depreciation and amortization expenses of $190,112.00 illustrating the wear and tear of its assets. The EBITDA ratio is 0.00 highlighting the company's operational efficiency. In terms of its market positioning, the stock is affordable at $0.90 making it suitable for budget-conscious investors. The stock also enjoys a high average trading volume of 8,403,143.00 indicating strong liquidity and interest from investors. With a market capitalization of $1,077,345,280.00 the company is classified as a small-cap player, which may offer unique investment opportunities. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape and demonstrating its potential for growth. Furthermore, it belongs to the Healthcare sector, driving innovation and advancement within its field.

What is 180 Life Sciences Corp. (ATNF)'s current stock price?

The current stock price of 180 Life Sciences Corp. (ATNF) is $7.04 as of 2025-08-15. Prices may fluctuate during the trading day. For real-time updates, check your brokerage platform or financial news websites.

Analysts predict 180 Life Sciences Corp. stock to fluctuate between $0.66 (low) and $17.75 (high) in the next 365 days, reflecting market expectations and potential volatility.

As of 2025-08-15, 180 Life Sciences Corp.'s market cap is $1,077,345,280, based on 153,032,000 outstanding shares.

Compared to Meta Platforms, Inc. Class A Common Stock, 180 Life Sciences Corp. has a Lower Market-Cap, indicating a difference in performance.

To buy 180 Life Sciences Corp. (ATNF) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ATNF. Place an order (Market, Limit, etc.).

The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.

180 Life Sciences Corp.'s last stock split was 1:19 on 2024-02-28.

Revenue: $0 | EPS: -$15.49 | Growth: -70.55%.

Visit https://180lifesciences.com/investor-relations for detailed financial reports.

You can explore historical data from here

All-time high: $3,382 (2021-08-09) | All-time low: $0.66 (2025-04-09).

Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.


News

ATNF

prnewswire.com

180 Life Sciences Closes $425 Million Private Placement to Advance its Ethereum Treasury Strategy

Company intends to use the net proceeds from this financing primarily to rapidly increase its ETH holdings Company plans to execute a differentiated yield generation program, with Company built for the Ethereum community, by the Ethereum community PALO ALTO, Calif. , Aug. 4, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (Nasdaq: ATNF), (the "Company" or "ETHZilla"), has closed its previously announced private placement, raising $425 million in gross proceeds, before placement agent fees and offering expenses (the "Private Placement") through a private investment in public equity transaction ("PIPE") for the purchase and sale of common stock and pre-funded warrants, as applicable, at a purchase price of $2.65 per share.

ATNF

prnewswire.com

180 Life Sciences Announce an Upsized $425 Million Private Placement to Establish an Ether Treasury Reserve Led by Consortium of Digital Asset Leaders to Launch ETHZilla

180 Life Sciences announces entry into PIPE funding documents to raise $425 million in gross proceeds to launch next generation Ethereum treasury strategy and planned rebranding to ETHZilla PALO ALTO, Calif. , July 29, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (Nasdaq: ATNF) (the "Company" or "180 Life Sciences") today announced that it plans to adopt a treasury policy under which the principal holding in its treasury reserve will be Ether ("ETH"), the native digital asset of Ethereum.

ATNF

accessnewswire.com

180 Life Sciences Corp. Announces Strengthening of Legacy Intellectual Property Assets

PALO ALTO, CA / ACCESS Newswire / July 1, 2025 / 180 Life Sciences Corp. (NASDAQ:ATNF) ("180" or the "Company), an innovative biotechnology company that is currently pivoting to the global iGaming sector, today announced two significant value enhancements to its existing, legacy intellectual property ("IP") portfolio-reinforcing part of the Company's strategy relating to continuing to build shareholder value through scientific innovation and patent protection for legacy IP assets. These new developments reflect 180's ongoing efforts to secure strong IP rights for its novel IP, while also positioning these assets for potential future partnering, licensing, or strategic transactions aimed at maximizing value for shareholders while the Company focuses on the global iGaming sector.

ATNF

accessnewswire.com

180 Life Sciences Corp. Announces Notice of Allowance for U.S. Patent Covering Novel Method to Prevent or Reduce Post-Operative Cognitive Dysfunction

PALO ALTO, CA / ACCESS Newswire / May 1, 2025 / 180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences" or the "Company"), an innovative media and entertainment company focused on the global iGaming sector, with certain legacy biotechnology intellectual property assets, today announced that the United States Patent and Trademark Office ("USPTO") has issued an official Notice of Allowance for U.S. Patent Application No. 17/556,584, covering a novel method for preventing or reducing Post-Operative Cognitive Dysfunction ("POCD").

ATNF

accessnewswire.com

180 Life Sciences Corp. Announces Share Repurchase

PALO ALTO, CALIFORNIA / ACCESS Newswire / April 30, 2025 / 180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences," the "Company," "we," or "us") today announced that it has entered into a Settlement and Mutual Release Agreement (the "Agreement") with Elray Resources, Inc. ("Elray") and Luxor Capital, LLC ("Luxor"). The Agreement strengthens and simplifies the Company's capital structure through a significant repurchase of shares.

ATNF

accesswire.com

180 Life Sciences Corp. Announces Pricing of $2.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under NASDAQ Rules

PALO ALTO, CA / ACCESSWIRE / December 27, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced that it has entered into a securities purchase agreement with several institutional investors to sell 1,200,000 shares of common stock in a registered direct offering priced at market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue unregistered warrants to purchase up to an aggregate of 1,200,000 shares of common stock.

ATNF

accesswire.com

180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules

PALO ALTO, CA / ACCESSWIRE / December 12, 2024 / 180 Life Sciences Corp. ("180" or the "Company") is pleased to announce that it has regained compliance with Nasdaq Listing Rule 5605(c)(2), which requires Nasdaq listed companies to maintain an audit committee consisting of three independent directors. This development follows the recent appointment of Mr.

ATNF

accesswire.com

180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors

PALO ALTO, CA / ACCESSWIRE / December 4, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced the appointment of Stephen Shoemaker to its Board of Directors, effective December 3, 2024. Mr. Shoemaker brings to 180 a wealth of experience as a seasoned senior executive and board member with a diverse background spanning finance, operations management, capital raising, and strategic planning.

ATNF

accesswire.com

180 Life Sciences Corp. Appoints Mr. Jay Goodman to Board of Directors

PALO ALTO, CA / ACCESSWIRE / October 29, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF) today announced the appointment of Mr. Jay Goodman to its Board of Directors, effective immediately.

ATNF

accesswire.com

180 Life Sciences Corp. Interim CEO, Blair Jordan, Issues Letter to Stockholders; Provides Update on Newly Acquired Gaming Technology Platform

PALO ALTO, CA / ACCESSWIRE / October 16, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF)("180" or the "Company"), today released the following letter to stockholders from its Interim Chief Executive Officer, Blair Jordan. Dear Stockholders: We are excited to announce that 180 is planning to strategically enter into the online gaming industry, utilizing its newly acquired "back-end" gaming platform, which incorporates blockchain technology and full cryptocurrency operability (the "Gaming Technology Platform").

See all news

logo
Stocks, Indicators, Pattern screeners all at one place
Stock Screener
Forex Screener
Crypto Screener